Ghent University Academic Bibliography

Advanced

Soluble mesothelin, megakaryocyte potentiating factor, and osteopontin as markers of patient response and outcome in mesothelioma

Kevin Hollevoet UGent, Kristiaan Nackaerts, ROBERT GOSSELIN UGent, Walter De Wever, Lionel Bosquée, Paul De Vuyst, Paul Germonpré, Eliane Kellen, Catherine Legrand and Yoshiro Kishi, et al. (2011) JOURNAL OF THORACIC ONCOLOGY. 6(11). p.1930-1937
abstract
Introduction: Soluble mesothelin (SM), megakaryocyte potentiating factor (MPF), and osteopontin (OPN) are blood biomarkers of mesothelioma. This study evaluates their use as markers of response to therapy and outcome. Methods: Sixty-two patients with malignant pleural mesothelioma were included in an observational multicenter study. Blood samples and matched computed tomography scans were collected at diagnosis and, when possible, during and after therapy. For each patient, the best overall radiological response was compared with the changes in serum SM, MPF, and plasma OPN levels across corresponding time points. Results: In five patients, blood sampling was done shortly before and after extrapleural pneumonectomy. SM and MPF levels markedly decreased after surgery, whereas OPN levels showed a median increase. Fifty-seven patients were surveilled during (and after) chemotherapy, of whom 27 (47%) had stable disease, 14 (25%) partial response, and 16 (28%) progressive disease. In patients with stable disease, SM and MPF levels did not change significantly across the corresponding time points, whereas OPN levels significantly decreased. In those with partial response, SM and MPF levels significantly decreased, whereas OPN levels showed no significant change. In patients with progressive disease, all three biomarker levels significantly increased. Patient responses correlated with a 15% change in all three biomarkers, although SM and MPF appeared more accurate than OPN. Low baseline OPN levels were independently associated with favorable progression-free survival and overall survival. Neither SM nor MPF showed prognostic value. Conclusions: SM and MPF levels were more closely associated with disease course than OPN and might prove useful in monitoring patient response in mesothelioma. Baseline OPN levels were an independent negative predictor of survival. These promising results require further validation.
Please use this url to cite or link to this publication:
author
organization
year
type
journalArticle (original)
publication status
published
subject
keyword
PHASE-III, Megakaryocyte potentiating factor, Osteopontin, Monitoring, Response, LUNG-CANCER, MALIGNANT-PLEURAL-MESOTHELIOMA, Prognosis, TUMOR-MARKER, SERUM MESOTHELIN, SOLID TUMORS, OVARIAN-CANCER, RECIST CRITERIA, CISPLATIN, Mesothelioma, DIAGNOSIS, Biomarker, Mesothelin
journal title
JOURNAL OF THORACIC ONCOLOGY
J. Thorac. Oncol.
volume
6
issue
11
pages
1930 - 1937
Web of Science type
Article
Web of Science id
000296700400021
JCR category
RESPIRATORY SYSTEM
JCR impact factor
3.661 (2011)
JCR rank
9/48 (2011)
JCR quartile
1 (2011)
ISSN
1556-0864
DOI
10.1097/JTO.0b013e3182272294
language
English
UGent publication?
yes
classification
A1
copyright statement
I have transferred the copyright for this publication to the publisher
id
2100334
handle
http://hdl.handle.net/1854/LU-2100334
date created
2012-05-07 15:37:45
date last changed
2012-10-22 10:44:44
@article{2100334,
  abstract     = {Introduction: Soluble mesothelin (SM), megakaryocyte potentiating factor (MPF), and osteopontin (OPN) are blood biomarkers of mesothelioma. This study evaluates their use as markers of response to therapy and outcome. 
Methods: Sixty-two patients with malignant pleural mesothelioma were included in an observational multicenter study. Blood samples and matched computed tomography scans were collected at diagnosis and, when possible, during and after therapy. For each patient, the best overall radiological response was compared with the changes in serum SM, MPF, and plasma OPN levels across corresponding time points. 
Results: In five patients, blood sampling was done shortly before and after extrapleural pneumonectomy. SM and MPF levels markedly decreased after surgery, whereas OPN levels showed a median increase. Fifty-seven patients were surveilled during (and after) chemotherapy, of whom 27 (47\%) had stable disease, 14 (25\%) partial response, and 16 (28\%) progressive disease. In patients with stable disease, SM and MPF levels did not change significantly across the corresponding time points, whereas OPN levels significantly decreased. In those with partial response, SM and MPF levels significantly decreased, whereas OPN levels showed no significant change. In patients with progressive disease, all three biomarker levels significantly increased. Patient responses correlated with a 15\% change in all three biomarkers, although SM and MPF appeared more accurate than OPN. Low baseline OPN levels were independently associated with favorable progression-free survival and overall survival. Neither SM nor MPF showed prognostic value. 
Conclusions: SM and MPF levels were more closely associated with disease course than OPN and might prove useful in monitoring patient response in mesothelioma. Baseline OPN levels were an independent negative predictor of survival. These promising results require further validation.},
  author       = {Hollevoet, Kevin and Nackaerts, Kristiaan and GOSSELIN, ROBERT and De Wever, Walter and Bosqu{\'e}e, Lionel and De Vuyst, Paul and Germonpr{\'e}, Paul and Kellen, Eliane and Legrand, Catherine and Kishi, Yoshiro and Delanghe, Joris and Van Meerbeeck, Jan},
  issn         = {1556-0864},
  journal      = {JOURNAL OF THORACIC ONCOLOGY},
  keyword      = {PHASE-III,Megakaryocyte potentiating factor,Osteopontin,Monitoring,Response,LUNG-CANCER,MALIGNANT-PLEURAL-MESOTHELIOMA,Prognosis,TUMOR-MARKER,SERUM MESOTHELIN,SOLID TUMORS,OVARIAN-CANCER,RECIST CRITERIA,CISPLATIN,Mesothelioma,DIAGNOSIS,Biomarker,Mesothelin},
  language     = {eng},
  number       = {11},
  pages        = {1930--1937},
  title        = {Soluble mesothelin, megakaryocyte potentiating factor, and osteopontin as markers of patient response and outcome in mesothelioma},
  url          = {http://dx.doi.org/10.1097/JTO.0b013e3182272294},
  volume       = {6},
  year         = {2011},
}

Chicago
Hollevoet, Kevin, Kristiaan Nackaerts, ROBERT GOSSELIN, Walter De Wever, Lionel Bosquée, Paul De Vuyst, Paul Germonpré, et al. 2011. “Soluble Mesothelin, Megakaryocyte Potentiating Factor, and Osteopontin as Markers of Patient Response and Outcome in Mesothelioma.” Journal of Thoracic Oncology 6 (11): 1930–1937.
APA
Hollevoet, K., Nackaerts, K., GOSSELIN, R., De Wever, W., Bosquée, L., De Vuyst, P., Germonpré, P., et al. (2011). Soluble mesothelin, megakaryocyte potentiating factor, and osteopontin as markers of patient response and outcome in mesothelioma. JOURNAL OF THORACIC ONCOLOGY, 6(11), 1930–1937.
Vancouver
1.
Hollevoet K, Nackaerts K, GOSSELIN R, De Wever W, Bosquée L, De Vuyst P, et al. Soluble mesothelin, megakaryocyte potentiating factor, and osteopontin as markers of patient response and outcome in mesothelioma. JOURNAL OF THORACIC ONCOLOGY. 2011;6(11):1930–7.
MLA
Hollevoet, Kevin, Kristiaan Nackaerts, ROBERT GOSSELIN, et al. “Soluble Mesothelin, Megakaryocyte Potentiating Factor, and Osteopontin as Markers of Patient Response and Outcome in Mesothelioma.” JOURNAL OF THORACIC ONCOLOGY 6.11 (2011): 1930–1937. Print.